European equities traded in the US as American depositary receipts were tracking lower late Wednesday, declining 0.38% to 1,481.07 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and internet advertising firm Criteo (CRTO), which rose 4.2% and 2.4%, respectively. They were followed by biopharmaceutical company Grifols (GRFS) and oil and gas company TotalEnergies (TTE), which were up 1.7% and 1.2%, respectively.
The decliners from continental Europe were led by medical device maker EDAP TMS (EDAP) and biopharmaceutical firm DBV Technologies (DBVT), which fell 3.6% and 3.2%, respectively. They were followed by consumer goods company Unilever (UL) and semiconductor company Sequans Communications (SQNS), which were down 1.3% and 1%, respectively.
From the UK and Ireland, the gainers were led by biotech company Autolus Therapeutics (AUTL) and biopharmaceutical firm Bicycle Therapeutics (BCYC), which increased 4.2% and 3.6%, respectively. Biopharmaceutical firms Mereo BioPharma Group (MREO) and Verona Pharma (VRNA) rose 3.5% and 2.8%, respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and financial services company Lloyds Banking Group (LYG), which lost 9.1% and 5.1% respectively. They were followed by utilities company National Grid (NGG) and biotech company Trinity Biotech (TRIB), which dropped 4.4% and 3% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.